bpc-157 clinical trials recruiting Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics BPC-157 – No Proof Required!
Description
doi:10.1016/j.molimm.2009.09.034
Integr Med (Encinitas)
KPV: CAS 67763-96-6 | MW ~358.4 g/mol
PMID 15483636
Studies have administered the peptide continuously for weeks to months without documented toxicity in standard markers (liver enzymes, renal function, haematological parameters)
